RxDoctor Payments Data

Tuan Nguyen, MD

Interventional Cardiology · Fountain Valley, CANPI 1669644951

Payments from drug & device makers

$3,943in general payments, 2019–2025

Across 124 payments — averaging $31.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$600
  • Novartis$598
  • AstraZeneca$432
  • Boehringer Ingelheim$346
  • GSK$254
  • Inari Medical, Inc.$240
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,938100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,943 in reported general payments places this provider in the 30th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,731,790
Medicare patients
2,277
Services billed
18,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban770$765,792
BrilintaTicagrelor226$185,400
EntrestoSacubitril/Valsartan139$133,776
JardianceEmpagliflozin141$127,286
XareltoRivaroxaban88$106,564
FarxigaDapagliflozin Propanediol29$28,604
Ranolazine ErRanolazine152$14,469
CorlanorIvabradine Hcl12$12,940
VascepaIcosapent Ethyl16$12,421
Breo ElliptaFluticasone/Vilanterol16$9,485
Metoprolol Succinate664$7,473
Amiodarone Hcl228$6,056
Nifedipine ErNifedipine226$5,181
Losartan Potassium472$4,640
Diltiazem Hcl116$3,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$432$214,005255 claims
NovartisEntresto$598$133,776139 claims
Boehringer IngelheimJardiance$346$127,286141 claims
Johnson & JohnsonXarelto$227$106,56488 claims
AmgenCorlanor$164$12,94012 claims
GSKBreo Ellipta$254$9,48516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →